Bessemer Group
SRNE

Bessemer Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bessemer Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,050
Closed -$22K – 1487
2016
Q1 		$22K Buy
+4,050
New +$23.5K ﹤0.01% 1048

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Bessemer Group's SRNE Position: Q2 2016 in Review

Bessemer Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2016, closing a stake of 4,050 shares — an estimated $22K sold.

Bessemer Group first reported a position in SRNE in Q1 2016 and held it in 1 quarter. The position peaked at $22K in Q1 2016. 62 funds tracked by Wall St. Rank hold SRNE as of Q2 2016.

  • Bessemer Group reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Bessemer Group sold 4,050 Sorrento Therapeutics, Inc. shares in Q2 2016, an estimated $22K.
  • Bessemer Group first reported a position in Sorrento Therapeutics, Inc. in Q1 2016 and held it in 1 quarter.
  • Bessemer Group's Sorrento Therapeutics, Inc. position peaked at $22K in Q1 2016.
  • 62 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.